Selected Publications

Academic Article

Year Title Altmetric
2022 Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerCancer Discovery.  12:2586-2605. 2022
2022 Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancerCancer Research.  82:p5-07-01-p5-07-01. 2022
2021 Abstract IA-003: Proteogenomic characterizations of pancreatic ductal adenocarcinomaCancer Research.  81:ia-003-ia-003. 2021
2021 Proteogenomic characterization of pancreatic ductal adenocarcinoma.Cell.  184:5031-5052.e26. 2021
2021 A proteogenomic portrait of lung squamous cell carcinoma.Cell.  184:4348-4371.e40. 2021
2021 Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistanceCancer Research.  81:2992-2992. 2021
2021 Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma.Cancer Cell.  39:361-379.e16. 2021
2021 Temporal Transcriptome Analysis Reveals Dynamic Gene Expression Patterns Driving β-Cell Maturation.Frontiers in Cell and Developmental Biology.  9:648791. 2021
2020 Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted TherapyCell.  183:1436-1456.e31. 2020
2020 Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). 2020
2020 Myt Transcription Factors Prevent Stress-Response Gene Overactivation to Enable Postnatal Pancreatic β Cell Proliferation, Function, and Survival.Developmental Cell.  53:390-405.e10. 2020
2020 Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability.Cell Reports Medicine.  1. 2020
2020 Proteogenomic Characterization of Endometrial Carcinoma.Cell.  180:729-748.e26. 2020
2020 Abstract GS2-05: Microscaled proteogenomic methods for precision oncologyCancer Research.  80:gs2-05-gs2-05. 2020
2020 Microscaled proteogenomic methods for precision oncology.Nature Communications.  11:532. 2020
2020 A multiomics comparison between endometrial cancer and serous ovarian cancer.PeerJ.  8:e8347. 2020
2019 Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.Cell.  179:964-983.e31. 2019
2019 Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma.Cell.  179:561-577.e22. 2019
2019 Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivityCancer Research.  79:4258-4270. 2019
2019 Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities.Cell.  177:1035-1049.e19. 2019
2019 Predictors of seizure recurrence in patients with surgery for focal cortical dysplasia: pairwise and network meta-analysis and trial sequential analysis.Child's Nervous System.  35:753-767. 2019
2019 Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.Journal for ImmunoTherapy of Cancer.  7:10. 2019
2019 Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape.OncoImmunology.  8:e1568809. 2019
2018 Synaptotagmin 4 Regulates Pancreatic β Cell Maturation by Modulating the Ca2+ Sensitivity of Insulin Secretion Vesicles.Developmental Cell.  45:347-361.e5. 2018
2017 Effective Isolation of Functional Islets from Neonatal Mouse Pancreas.Journal of Visualized Experiments2017
2016 Novel Insights into NeuN: from Neuronal Marker to Splicing Regulator.Molecular Neurobiology.  53:1637-1647. 2016
2015 Endothelial cells control pancreatic cell fate at defined stages through EGFL7 signaling.Stem Cell Reports.  4:181-189. 2015

Research Overview

  • Our research focuses on the proteogenomic understanding of cancer biology and treatment innovation. The past two decades have witnessed the progression of personalized tumor therapy driven by advanced genomic studies (e.g. the TCGA). However, the understanding of tumor systems biology at protein level remains a knowledge gap. Since postdoc, I have been among the leading data analytic team of the Clinical Proteomic Tumor Analysis Consortium (CPTAC), which uses mass spectrometry (MS)-based proteomics to profile the global protein expression and post-translational modifications (PTMs) for multiple cancer types. Integrating these proteomic data to genomic knowledge, we have brought the proteogenomic research to an unprecedented level for protein marker and drug target discovery. Currently in the lab, we strive to improve the computational approaches for tumor proteogenomic data analysis and the clinical translation of proteogenomic findings. Specifically, our projects will drive the functional interpretation of genomic aberration, signaling pathway understanding by protein and PTM dynamics, and immunotherapeutic target discovery and drug repurposing, all of which will see the advancement of integration between genomics and proteomics.
  • Education And Training

  • Doctor of Science in Cell / Cellular and Molecular Biology, Vanderbilt University 2017
  • Master of Sciences or Mathematics in Molecular Biology, 2010
  • Bachelor of Science or Mathematics in Biology, 2007
  • Full Name

  • Chen Huang